12
Apr
2023
The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen
Today’s guest on The Long Run is Catherine Stehman-Breen. Catherine is the CEO of Boston-based Chroma Medicine. Chroma is working on therapies that control gene expression through epigenetic editing. People have heard a lot about editing of the genome with CRISPR, and then subsequent refinements of the technology known as base editing and prime editing. The question at Chroma is... Read More
12
Apr
2023
Function Gets $28M to Make Personalized Cancer Genomics to the Next Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2023
CRISPR, Vertex Seek FDA Milestone, Canaan Pulls in $850M, & Cutting Out the Middleman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Mar
2023
Timmerman Traverse for Life Science Cares is Back
The next biotech team adventure is here. I’m thrilled to announce the Timmerman Traverse for Life Science Cares 2023. We’re on a mission to raise $1 million. We’re giving it all back to the most vulnerable people in the communities where we live and work. This trip involves shared sacrifice. We will cover 20+ miles and gain 8,000 feet of... Read More
28
Mar
2023
Treating a Common, Underappreciated Disease: Eric Dobmeier on The Long Run
Today’s guest on The Long Run is Eric Dobmeier. Eric is the CEO of Seattle-based Chinook Therapeutics. Chinook is seeking to develop drugs for kidney diseases. About 10 percent of people on Earth are estimated to have some degree of chronic kidney disease. It ranges from mild forms all the way through end-stage renal disease that requires dialysis. America spends... Read More
22
Mar
2023
Flare Therapeutics Gets $123M to Make Drugs Against Elusive Transcription Factors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2023
Takeda Oral Tyk2 Inhibitor, Acquired in Nimbus Deal, Raises the Bar on Psoriasis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2023
Pfizer Acquires Seagen, Sanofi & Novo Cut Insulin Prices, & Illumina’s Proxy Fight
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Mar
2023
Big Pharma, VCs Bet $105M on Mediar’s Antibodies for Fibrotic Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2023
The Future of Neuroscience Drug R&D: Ryan Watts on The Long Run
Today’s guest on The Long Run is Ryan Watts. Ryan is the co-founder and CEO of South San Francisco-based Denali Therapeutics. Denali is one of the prominent development-stage biotech companies working on treatments for neurodegenerative diseases. It has a pipeline with seven drug candidates in clinical development. It’s developing small molecules and large molecules against a range of neurodegenerative diseases... Read More
9
Mar
2023
SVB’s Dark Day, Biogen’s Leadership Change, and a Plan to Crush HepC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2023
Third Rock, Arch, J&J Pump $100M into Rapport to Develop Precision Neuro Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Mar
2023
Lilly Cuts Insulin Prices, Reata’s Dramatic FDA Approval, & Seagen M&A Rumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2023
A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run
Today’s guest on The Long Run is David Hallal. David is the CEO of Waltham, Mass.-based ElevateBio. ElevateBio describes itself as a technology-driven company for cell therapies. It has pulled together gene editing tools, induced pluripotent stem cells, and various viral vectors necessary to modify cells to fight cancer or treat other diseases. David co-founded ElevateBio in 2017 with Mitchell... Read More
14
Feb
2023
Engineered B-Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run
Today’s guest on The Long Run is Joanne Smith-Farrell. Joanne is the CEO of Cambridge, Mass.-based Be Biopharma. Many listeners of this show are familiar with the explosion of activity in cell therapy. Engineered T cell therapies have delivered extraordinary results for people with certain types of cancer. The success in these personalized T cell therapies, which get modified outside... Read More
2
Feb
2023
GSK, Lilly Win FDA Approvals, Magenta For Sale, and a Colossal Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2023
A Biotech Journalism Outlet Built to Last: Rick Berke on The Long Run
Today’s guest on The Long Run is Rick Berke. Rick is the co-founder and executive editor of STAT. Just about everyone who listens to The Long Run probably already reads STAT. If you don’t, you should. It’s become a go-to publication for breaking news, features, and in-depth investigative reporting across the world of biotech and healthcare. John Henry, the billionaire... Read More
26
Jan
2023
VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2023
Dimension Debuts with $350M to Back Startups at Bio & Tech Nexus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jan
2023
From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run
Today’s guest on The Long Run is Jeb Keiper. Jeb is the CEO of Boston-based Nimbus Therapeutics. Nimbus made news in December 2022 when it sold its experimental Tyk2 inhibitor to Takeda Pharmaceuticals for $4 billion upfront and $2 billion in potential milestones. The drug’s value skyrocketed when it hit the primary endpoint of a Phase 2b clinical trial for... Read More